Publications by authors named "Zaniqua Bullock"
Background/objectives: Checkpoint inhibitors, which generate durable responses in many cancer patients, have revolutionized cancer immunotherapy. However, their therapeutic efficacy is limited, and immune-related adverse events are severe, especially for monoclonal antibody treatment directed against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which plays a pivotal role in preventing autoimmunity and fostering anticancer immunity by interacting with the B7 proteins CD80 and CD86. Small molecules impairing the CTLA-4/CD80 interaction have been developed; however, they directly target CD80, not CTLA-4.
View Article and Find Full Text PDFArticle Synopsis
- The Nav channel is vital for starting and spreading action potentials in neurons, with the α subunit requiring auxiliary proteins for full function.
- A specific protein-protein interaction between Nav1.6 and fibroblast growth factor 14 (FGF14) is crucial for neuron excitability in the brain.
- Peptides derived from FGF14, namely PLEV and EYYV, can inhibit this interaction and modulate Nav1.6 activity, indicating potential for developing new targeted treatments.